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MaThis review summarizes evidence from 2 lines of research previously thought to be unrelated: the unexpectedly positive
results of TACT (Trial to Assess Chelation Therapy), and a body of epidemiological data showing that accumulation of
biologically active metals, such as lead and cadmium, is an important risk factor for cardiovascular disease. Considering
these 2 areas of work together may lead to the identiﬁcation of new, modiﬁable risk factors for atherosclerotic cardio-
vascular disease. We examine the history of chelation up through the report of TACT. We then describe work connecting
highermetal levels in the body with the future risk of cardiovascular disease. We conclude by presenting a brief overview of
a newly planned National Institutes of Health trial, TACT2, in which we will attempt to replicate the ﬁndings of TACT and to
establish that removal of toxic metal stores from the body is a plausible mechanistic explanation for the beneﬁts of edetate
disodium treatment. (J Am Coll Cardiol 2016;67:2411–8) © 2016 by the American College of Cardiology Foundation.O n November 4, 2012, the TACT (Trial toAssess Chelation Therapy) investigators re-ported publicly the ﬁrst large, randomized,
placebo-controlled trial evidence that edetate diso-
dium (disodium ethylenediaminetetraacetic acid)
chelation therapy signiﬁcantly reduced cardiac
events in stable post–myocardial infarction (MI) pa-
tients. These results were so unexpected that many
in the cardiology community greeted the report
initially with either skepticism (it is probably wrong)
or outright disbelief (it is deﬁnitely wrong) (1). The
TACT trial had been controversial since the
announcement of its funding in 2002. The primary
justiﬁcation used by the National Center for Comple-
mentary and Alternative Medicine and the National
Heart, Lung, and Blood Institute for the study was
that it was being conducted to prove that chelation
did not work, so that the many patients who sought
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ABBR EV I A T I ON S
AND ACRONYMS
MI = myocardial infarction
NHANES = National Health and
Nutrition Examination Survey
NNT = number needed to treat
OMVM = active oral
multivitamins and minerals
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related theories in our understanding of ther-
apeutic effectiveness. For any set of experi-
mental observations (including clinical trial
results), many “explanatory” pathophysio-
logical models can be proposed to ﬁt the
known facts. Thus, mature pathophysiolog-
ical models deﬁning therapeutic mechanisms
are not necessary to demonstrate that a ther-apy is effective. Furthermore, the history of medicine
is replete with examples where unexpected ﬁndings
led to both novel therapeutic discoveries and previ-
ously unsuspected mechanisms (3). Thalidomide
and sildenaﬁl are 2 well-known examples where cur-
rent clinical utility was discovered essentially by acci-
dent. We believe that edetate disodium chelation
therapy for atherosclerotic disease may provide
another example of this phenomenon.
We brieﬂy summarize evidence from 2 previously
unrelated lines of research: the unexpectedly positive
results of the TACT trial, and a body of epidemiolog-
ical data showing that accumulation of biologically
active metals, such as lead and cadmium, is an
important risk factor for cardiovascular disease.
We believe that considering these 2 areas of work
together may lead to the identiﬁcation of a major
new modiﬁable risk factor for atherosclerotic car-
diovascular disease. We start by reviewing the his-
tory of chelation up through the report of TACT. We
then describe work connecting higher metal levels
in the body with the future risk of cardiovascular
disease. We conclude by presenting a brief overview
of a newly funded National Institutes of Health
trial, TACT2, in which we will attempt to replicate
the ﬁndings of TACT and establish that removal of
toxic metal stores from the body is a plausible
mechanistic explanation for the beneﬁts of edetate
disodium treatment.
BRIEF HISTORY OF CHELATION
Metal ions that enter the body from the environment
can bind to many of the molecules in body tissues,
including proteins and polysaccharides. Furthermore,
many of these metals are biologically active, partici-
pating in a variety of different physiological and
pathophysiological reactions. Chelation, in the
context of medical therapeutics, is a process in which
the organic chelator molecules are introduced into
the blood, where they bind the target metal ions with
high afﬁnity. The complex of chelator and metal ion
remains in the blood compartment until ﬁltered by
the kidneys or excreted by the liver, thus removing
the metal ions from the body. Edetate disodium, asynthetic chelating agent ﬁrst synthesized in Ger-
many in the 1930s, has up to 6 binding sites with
which to hold and envelop metal ions (4).
The medical utility of edetate disodium was only
discovered after some trial and error. After World War
II, the U.S. Navy discovered that edetate disodiumwas
effective in treating lead poisoning in naval shipyard
workers using lead-based paint (5). The ﬁrst paper on
the use of intravenous infusions of edetate disodium
to treat atherosclerotic heart disease, published in
1956 by Clarke et al. (6), reported improvement in 19 of
20 patients with angina. The authors noted the
delayed onset of therapeutic effect, requiring about 20
infusions before clinical effects became evident. At
that time, there were no effective treatments for cor-
onary disease. Physicians did not uniformly view
cigarette smoking as atherogenic (7). Aspirin, statins,
and revascularization had not been developed as car-
diovascular therapies. Autopsied hearts from that era
demonstrated coronary arteries that were often pro-
foundly calciﬁed. This had given Clarke et al. (6) the
idea that perhaps edetate disodium was acting to
decalcify coronary obstructions and thereby relieve
angina. Subsequent investigations in the 1960s by a
different group in another small cohort found more
mixed results (8). Some patients still showed the
delayed symptomatic improvement reported earlier,
but the durability of the effect seemed quite variable
(in the context of no risk factor control), and the in-
vestigators felt that the prognosis of the patients in
this small case series had not been affected. The
therapy was ultimately considered “not useful” and
conventional medicine lost interest (9). Yet, edetate
chelation for atherosclerosis did not vanish.
Over the subsequent years, chelation and alterna-
tive medicine physicians implemented clinical pro-
tocols for safer use of edetate disodium, principally
restricting the dose and infusion rates (10). In the
1980s and 1990s, alternative medicine journals pub-
lished case reports and case series, mostly reporting
spectacular results in treating cardiovascular disease
(11). Patients continued to seek and physicians
continued to administer edetate disodium for various
indications, including atherosclerotic heart disease
(12). Within traditional cardiology, there were 3 small
trials performed to assess whether edetate disodium
treatments led to relief of angina or claudication (13–
15). Although nominally negative, these trials were
too small to exclude a small or even moderate-sized
beneﬁt in clinical endpoints for patients with
atherosclerotic cardiovascular disease (16).
In 2001, the National Center for Complementary
and Alternative Medicine, with cofunding from the
National Heart, Lung, and Blood Institute, released a
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TACT (Trial to Assess Chelation Therapy) Kaplan-Meier estimates of the primary composite
endpoint: edetate disodium (EDTA) chelation therapy versus placebo (2). The primary
endpoint was a composite of death from any cause, reinfarction, stroke, coronary revas-
cularization, or hospitalization for angina. CI ¼ conﬁdence interval.
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2413request for applications for a clinical trial of edetate
disodium chelation in cardiovascular disease. The
resulting trial, TACT, was funded in August 2002.
Because of the expectation that TACT would be a
debunking study, it was designed as a clinical trial
without a mechanistic component.
DESIGN AND RESULTS OF TACT
The request for applications called for testing the
most prevalent chelation solution and treatment
strategy. In 2002, clinical chelation practice most
commonly involved multiple administrations of an
edetate disodium-based infusion that contained
other components, including vitamin C, B vitamins,
heparin, electrolytes, and procaine. In addition,
chelating physicians also recommended high doses of
oral antioxidant vitamins and minerals to be taken
concurrently with the intravenous chelation treat-
ments. Therefore, a factorial design was selected for
TACT, in which eligible patients were randomly
assigned to 1 of 4 groups (17).
1. Active intravenous (IV) chelation infusions þ
active oral multivitamins and minerals (OMVM)
2. Active IV chelation infusions þ placebo OMVM
3. Placebo IV chelation infusions þ active OMVM
4. Placebo IV chelation infusions þ placebo OMVM
Eligible patients were at least 50 years of age,
had sustained an acute MI >6 weeks before the
enrollment date, and had a serum creatinine level
#2.0 mg/dl.
The treatment regimen consisted of 40 chelation or
placebo-based infusions administered as 30 weekly
infusions, followed by 10 additional maintenance in-
fusions, 2 to 8 weeks apart. OMVM were to be taken
daily throughout the duration of the trial. The
primary endpoint for the study was a composite of
all-cause mortality, MI, stroke, coronary revascul-
arization, or hospitalization for angina. The major
secondary endpoint was cardiovascular mortality,
stroke, or recurrent MI.
TACT enrolled 1,708 participants (839 in the che-
lation treatment group and 869 in the chelation pla-
cebo group) at 134 sites in the United States and
Canada. Study patients had a median age of 65 years,
18% were female, 9% were nonwhite, 37% were dia-
betic, and 83% had either a prior coronary bypass or
percutaneous coronary intervention. The trial
strongly encouraged concomitant use of conven-
tional, evidence-based post-MI cardiac therapies. At
baseline, 92% were taking aspirin, clopidogrel, or
warfarin, and 73% were taking statins. The median
low-density lipoprotein was 89 mg/dl. A total of55,222 placebo or active infusions were administered.
At least 30 infusions were completed by 76% of pa-
tients, and 65% completed all 40 infusions. Subjects
were followed for a median of 55 months.
Edetate chelation reduced the primary composite
endpoint by 18% (hazard ratio [HR]: 0.82; 95% conﬁ-
dence interval [CI]: 0.69 to 0.99; p ¼ 0.035); the
number needed to treat (NNT) to prevent 1 event over
5 years of follow-up was 18 (Figure 1). One intriguing
ﬁnding was that the event curves for edetate and
placebo continued to diverge even after the infusions
were completed, suggesting that edetate was altering
the risk for future cardiovascular events in structural
ways that did not depend on continued exposure to
the therapeutic agent. The comparison of 2 factorial
groups, chelation þ OMVM versus placebo þ placebo
demonstrated an even larger difference between
groups (HR: 0.74; 95% CI: 0.57 to 0.95; p ¼ 0.016),
with an NNT to prevent 1 event over 5 years of follow-
up of 12 (HR: 0.74; 95% CI: 0.57 to 0.95; p ¼ 0.016).
With regard to safety, the masked medical monitor
attributed 2 deaths to study therapy: 1 was in the
chelation group, and 1 in placebo.
RESULTS IN PATIENTS WITH DIABETES
A total of 633 TACT participants (37%) had diabetes, a
pre-speciﬁed subgroup. Diabetes was pre-speciﬁed
because it confers increased risk for cardiovascular
events, and not due to any information available to
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edetate disodium (2,18). Edetate disodium treatment
reduced the relative risk of the primary endpoint by
41% (HR: 0.59; 95% CI: 0.44 to 0.79; p ¼ 0.0002) over
5 years (Figure 2). The NNT to prevent 1 event over 5
years of follow-up was 6.5. The principal secondary
endpoint, cardiovascular death or recurrent MI or
stroke, occurred in 17% of placebo patients and 11% of
edetate disodium–treated patients, a 40% relative
reduction in risk (HR: 0.60; 95% CI: 0.39 to 0.91;
p ¼ 0.017). There was a 52% relative reduction in the
risk of recurrent MI among patients with diabetes
(HR: 0.48; 95% CI: 0.26 to 0.88; p ¼ 0.015), and a 43%
relative reduction in the risk of death from any cause
in patients with diabetes (HR: 0.57; 95% CI: 0.36 to
0.88; p ¼ 0.011). There was no difference between
groups in control of glucose, as deﬁned by fasting
glycemia, during the course of the initial 30 infusions.
WHAT DOES EDETATE DISODIUM CHELATE?
Although the treatment regimens tested in TACT
were complex, the most reasonable presumption is
that edetate disodium was the primary active thera-
peutic agent responsible for the results. To investi-
gate the chelating effect of edetate disodium, Waters
et al. (19) collected 24-h urines for 2 days before and 2
days after an edetate disodium–based infusion similar
to that used in TACT and analyzed the samples forEndpoint in Patients With Diabetes
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tes of the primary composite endpoint: EDTA chelation therapy versus
atients with diabetes (19). Abbreviations as in Figure 1.various toxic and essential metals. Following the
infusion, the excretion of lead over 2 days increased
by 3,830%, and of cadmium by 514%. A similar
experiment performed by Arenas et al. (20) demon-
strated similar results, but in this case with the
identical TACT solution in TACT-eligible patients.
Compared with baseline, a single infusion increased
lead excretion by 3,887%, and cadmium by 670%.
These ﬁndings raise the possibility that edetate diso-
dium mobilizes lead and cadmium from their chronic
tissue storage compartments and facilitates their
excretion. In our review, we focus on cadmium and
lead because those are the metals with the strongest
epidemiological and experimental evidence in sup-
port of a role in cardiovascular disease development.
EVIDENCE SUPPORTING TOXIC METALS
AS AN EMERGING CARDIOVASCULAR
RISK FACTOR
The association of environmental pollutants,
including metals, with cardiovascular disease has
been reviewed elsewhere (21,22). In this review, we
will summarize the evidence for the 2 metals that are
chelated most effectively by edetate disodium and
that have convincing published reports documenting
their cardiovascular toxicity: lead and cadmium,
ranked second and seventh, respectively, as envi-
ronmental chemicals of concern by the Agency for
Toxic Substances and Disease Registry (23).
LEAD SOURCES AND BIOLOGICAL STORAGE. Lead
exposure in the United States markedly increased
from the end of World War II through the mid-1970s,
largely the result of use of tetraethyl lead in gasoline
as an octane booster combined with the increased
number of automobiles in use (24). At the peak of lead
production, the atmospheric release of lead reached
600,000 tons annually (25). Lead exposure then
began to decrease following the elimination of lead in
gasoline for road-driven vehicles by 1980. The
half-life of lead in the body, however, is extremely
long, as lead is not excreted efﬁciently, and it accu-
mulates in bone. As a result, anyone living in the
United States during the period from 1945 to 1980
accumulated much more lead in his or her body than
has happened at any other time in history. Lead
exposure, moreover, remains ubiquitous through
soil, batteries, toys, house paint, plumbing, and in-
dustrial sources, as well as smoking and secondhand
smoke exposure (26).
Lead measured in whole blood is the major
biomarker of lead exposure, and has a half-life of 35
days. Blood lead accounts for only 1% to 5% of total
body lead burden, however, as most lead in the body
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The half-life for lead in bone approaches 30 years for
cortical bone and years to decades for trabecular bone
(27). Once in the chronic storage compartment, bone
lead leaches out over time, serving as an endogenous
source of blood lead and resulting in ongoing, years-
long low-level lead exposure to the cardiovascular
system, neural tissues, and kidneys. Lead can be
mobilized from the internal body stores and excreted
through the urine following chelation. Chelation with
edetate disodium, the chelating agent used in TACT
and proposed for TACT2, mobilizes lead from bone,
whereas other chelating agents, for instance 2,3-
dimercaptosuccinic acid, mobilize lead mostly from
soft tissues (28).
LEAD AND CARDIOVASCULAR DISEASE. The possible
association between lead and cardiovascular disease
has been recognized for many years (21,22,29). The
most robust studies evaluating the association of
blood lead with cardiovascular outcomes have been
conducted using data from the National Health and
Nutrition Examination Surveys (NHANES). NHANES
studies reported that despite the remarkable drop in
blood lead following the elimination of leaded gaso-
line, blood lead levels remain associated with car-
diovascular outcomes of atherosclerotic origin,
including coronary heart disease, hypertension,
stroke, and peripheral arterial disease (30,31).
Cumulative lead exposure, as reﬂected by bone
lead, and cardiovascular events have been studied in
the Veterans’ Normative Aging Study, a longitudinal
study among community-based male veterans in the
greater Boston area enrolled in 1963. Patients had a
single measurement of tibial and patellar bone lead
between 1991 and 1999 (32). The HR for ischemic
heart disease mortality comparing patellar lead >35 to
<22 mg/g was 8.37 (95% CI: 1.29 to 54.4).
Lead is an established risk factor for hypertension
on the basis of consistent epidemiological evidence in
populations around the world, as well as experi-
mental evidence showing increases in blood pressure
levels in animal models (29,33). Substantial in vivo
and in vitro evidence supports that lead reduces nitric
oxide bioavailability (34), as well as promotes oxida-
tive stress and inﬂammation. These mechanisms are
believed to play a major role in lead-related vascular
disease (Central Illustration). In experimental models,
lead-induced hypertension was reversible, either
with a chelating agent or with antioxidant treatment
(34). Recent studies suggest that there may be
epigenetic modiﬁcations due to lead exposure, for
instance, with hypomethylation in a promoter of the
COLIA2 gene (35).CADMIUM SOURCES AND BIOLOGICAL STORAGE.
Cadmium production markedly increased during the
20th century, especially between 1945 and the
1980s (36), as a result of cadmium use in the pro-
duction of nickel-cadmium batteries, metal coat-
ings, and plastic stabilizers. Food and smoking are
the major sources of cadmium for the general pop-
ulation (37). The potential toxicity of cadmium is
ampliﬁed by its extremely slow excretion rate. Once
ingested, cadmium is stored predominantly in the
kidneys, liver, lungs, pancreas, and central nervous
system, with a half-life for excretion of over 15 to
45 years (38,39). In blood, cadmium has 2 com-
partments, 1 that represents recent exposure and
has a half-life of w35 days and another that is in
equilibrium with internal cadmium stores and has a
half-life of decades.
CADMIUM AND CARDIOVASCULAR DISEASE. Several
studies have evaluated the association between cad-
mium and cardiovascular disease in the general U.S.
population using NHANES data (39–41). In NHANES
1988 to 1994, for every doubling of urine cadmium,
there was a 36% increase in coronary heart disease
mortality in men, but no increase was observed in
women. In NHANES 1999 to 2004, however, blood
and urine cadmium were associated with increased
cardiovascular disease mortality, including coronary
heart disease, in both men and women. In the Strong
Heart Study, participants with diabetes showed
stronger associations between cadmium and CVD
outcomes than did those without diabetes, and the
difference was statistically signiﬁcant (42).
Cadmium exposure has also been related to pe-
ripheral arterial disease. In NHANES analyses, it was
proposed that cadmium could potentially mediate at
least part of the effect of smoking on peripheral
arterial disease (41). A recent systematic review
concluded that the evidence supports the role of
cadmium as a cardiovascular disease risk factor,
especially for coronary heart disease (43).
Cadmium is thought to promote atherosclerosis
through oxidative mechanisms (44). Cadmium
can indirectly deplete antioxidants, such as gluta-
thione, increasing reactive oxygen species (Central
Illustration) (45). Subclinically, cadmium has been
related to early atherosclerosis, including higher
carotid intima-media thickness and carotid plaque in
women from Europe (44). In experimental studies,
low-level cadmium exposure can increase endothelial
permeability, inhibit proliferation of endothelial
cells, and induce cell death. Cadmium has also been
related to gene expression and differential methyl-
ation in genes encoding proteins involved in
CENTRAL ILLUSTRATION Heavy Metals as a Risk Factor for Atherosclerotic Cardiovascular
Disease and the Beneﬁts of Chelation Therapy
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Major sources and routes of exposure, mechanisms at the molecular and cellular level, responses at the tissue and organ level, and subclinical
and clinical cardiovascular effects on the basis of experimental and epidemiological evidence are shown for lead and cadmium. Arrows denote
direction of ﬂow. Na2EDTA ¼ disodium ethylene diamine tetra acetic acid; NO ¼ nitric oxide; TACT ¼ Trial to Assess Chelation Therapy.
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vascular calciﬁcation (RASAL1 and Klotho) (46,47).
DIABETES AND METALS. Speciﬁc adverse effects of
metals in patients with diabetes mellitus have been
discussed for over 20 years. Complications of diabetes
mellitus may be partially mediated through the accu-
mulation of advanced glycation end-products and
activation of the receptor of advanced glycation
end-products (48), with downstream inﬂammatory
cascades (49,50). Glycation end-products are created
by the nonenzymatic interaction of glucose with pro-
teins, lipids, and nucleic acids (51). Most advanced
glycation end-products require metal-catalyzed oxy-
gen chemistry for their formation. Metals bind toglycation end-products and promote the formation of
reactive oxygen species in an autocatalytic reaction.
The resultant oxidized end-products accumulate in
tissues, where they promote inﬂammation and
oxidative stress, hallmarks of atherosclerosis. These
processes may provide a plausible explanation for
the ampliﬁed beneﬁt seen with edetate chelation in
the diabetic subgroup of TACT (18,52,53). This is a
hypothesis that merits testing. A direct connection
to lead and cadmium has yet to be demonstrated.
REPLICATION OF TACT: THE TACT2 STUDY
The hallmark of science is replication, and so it needs
to be with the use of edetate disodium chelation as a
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2417treatment to reduce cardiovascular risk. We recently
received funding through the National Center for
Complementary and Integrative Health for a planning
year for TACT2, a replicative study in post-MI diabetic
patients comparing the TACT regimen with placebo.
Although the ﬁnal protocol is still under develop-
ment, there is agreement that TACT2 should replicate
the most encouraging ﬁndings from TACT as closely
as possible. We have proposed a similar 2  2 factorial
design for TACT2, randomly assigning patients to 40
infusions of the TACT chelation solution versus pla-
cebo infusions and high doses of OMVM versus oral
placebo. TACT2 will also begin to explore the most
likely mechanistic hypotheses. We have proposed
blood and urine collections throughout the infusion
period and will attempt to relate baseline lead and
cadmium levels to risk of future events. In addition,
we will perform analyses to determine whetherreduction in lead and cadmium levels is causally
associated with reduced cardiovascular risk. In
recognition that these are hypotheses that may be
disproven, a biorepository of specimens, including
deoxyribonucleic acid (DNA), has also been proposed.
If fully funded, the ﬁnal protocol will crystallize over
the coming months. At present, TACT2 is still seeking
enrollment sites.
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